Five years later, the approval of Wegovy made GLP-1 an ubiquitous term featured in every conversation about obesity
This makes it a more favourable choice compared to crisps, biscuits, or other refined carbohydrate snacks
Suggested Frequency To experience optimal benefits, we recommend: Weekly or bi-weekly sessions for 46 weeks Monthly maintenance thereafter The effects are cumulative, so consistency is key for long-lasting results
To get TRICARE to cover Wegovy or Zepbound for weight loss, you must meet these criteria: Clinical Requirements BMI of 30 or higher, OR BMI of 27 or higher with at least one weight-related condition (diabetes, hypertension, dyslipidemia, sleep apnea) Documentation Requirements Prescription from a TRICARE-authorized network provider Prior authorization form completed by your provider Evidence of previous weight loss attempts (typically diet and exercise for at least 6 months) Commitment to continue healthy lifestyle habits while on medication Initial approval period: 6 months
It's what it doesn't actually do
Several Indian companies are preparing to enter the market: Alkem Laboratories has started clinical trials for semaglutide and plans to launch close to patent expiration in March 2026. Biocon is developing its own version of Wegovy and aims to be one of the early players in the market, targeting a launch in 2026 or shortly after
